Lilly immunology deal starts Phase 1
Lilly’s $2.88 billion immunology deal has started Phase 1.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Lilly’s $2.88 billion immunology deal has started Phase 1.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.